Prescribing information

 

The mode of action for Xolair in CSU.

Xolair directly targets and binds to IgE,1–3 preventing histamine release.2,3

  • Xolair binds to free IgE, preventing it from binding to the FcεRI receptors on mast cells and basophils and results in downregulation of FcεRI receptors on these cells.1,3
  • The exact mechanism of action of Xolair in the treatment of CSU is uncertain, and improvements in symptoms are likely due to a combination of mechanisms.1,3,4

 

*Post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.5

Indication: Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1

CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.

References

  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics. 
  2. Chang TW et al. J Allergy Clin Immunol 2015;135(2):337–342. 
  3. Kaplan AP et al. Allergy 2017;72(4):519–533. 
  4. Kocatürk G et al. Turkderm-Turk Arch Dermatol Venereology 2018;52:112–119.
  5. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
XSU20-C010 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]